Company intelligence / Profile preview

Ocuphire Pharma

Farmington Hills, Michigan, United Statesir.ocuphire.com ↗

Ownership: Public · OCUP
Development stage: Phase 3

Overview

Ocuphire has FDA-approved RYZUMVI™ (phentolamine ophthalmic solution 0.75%) for treating pharmacologically induced mydriasis. The company has multiple Phase 3 trials ongoing for presbyopia and night vision disturbances, with data readouts expected in Q1 2025. Following acquisition of Opus Genetics, the company also has gene therapy candidates for inherited retinal diseases in Phase 1/2 trials.

Therapeutic areas: Ophthalmology
Modalities: Small moleculesGene therapy
Industry: Biotech

Drug pipeline

1 asset

Paremyd

Unknown

Partnerships

Viatris, Inc.Foundation Fighting Blindness

Financials

Market cap: $31.7M
Total revenue: $755K
Enterprise value: $-22.1M

Beyond the preview

Go deeper on Ocuphire Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocuphire Pharma.

Explore the full profile